Unlabelled: Choroidal effusion is an abnormal collection of fluid within the suprachoroidal potential space. It is a common complication following glaucoma filtering surgeries such as trabeculectomy. It is a clinical diagnosis that sometimes goes undetected or unreported, except when symptomatic. Reported incident rates is 7.9 - 18.8% for serous effusions and 0.7 - 3% for haemorrhagic effusions. This report aims to highlight a case of choroidal effusion after trabeculectomy and its management challenges.
Case Report: A seven year old boy presented to our facility with history of cloudy appearance of the right eye of five years duration. He was diagnosed with right infantile glaucoma. Intraocular pressures (IOP) were 44mmHg and 18mmHg right and left eyes respectively. Patient subsequently had right trabeculectomy. He developed hypotony at post-operative day two and a right choroidal effusion was noticed at post-operative day four. As a result of this, he initially had a right anterior chamber reformation with ocular viscoelastic on day seven. Later, a compression suture over the bleb and sclerostomy was performed 11 days post initial surgery. Choroidal effusion progressively regressed post-operatively and completely resolved at day five post-sclerostomy and effusion drainage.
Conclusion: Choroidal effusion is a common complication after trabeculectomy in which conservative management results in resolution. However, when conservative management fails, surgical intervention should not be delayed to maximize good outcome.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369399 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Orbital and Ocular Venous Congestion: A Rare Manifestation of Hypervascular Paget Disease of the Bone.
Ophthalmic Plast Reconstr Surg
January 2025
Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts.
A 73-year-old male with a history of incidentally diagnosed Paget disease of bone affecting the skull and left orbit 2 years prior presented with 3 months of vision loss, proptosis, and periorbital swelling of the OS. Examination showed best-corrected Snellen visual acuity of 20/150 in the affected eye, intact motility, 7 mm of relative proptosis, significant dilated and tortuous "corkscrew" conjunctival vessels, serous choroidal and retinal detachments, optic nerve hyperemia, and venous tortuosity and dilation. Although the bony lesions in the left orbit were stable from 1 year prior on imaging, the diagnostic angiogram demonstrated osseous blush and hypervascularity of the lesion.
View Article and Find Full Text PDFAhmed glaucoma valve implant for refractory glaucoma in children: A systematic review and meta-analysis.
Sci Prog
January 2025
School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Purpose: The aim of this study was to evaluate the efficacy and safety of the Ahmed glaucoma valve in pediatric patients with refractory glaucoma.
Methods: A comprehensive literature search was conducted across multiple major databases, including PubMed, Embase, the Cochrane Library of Systematic Reviews, Science Direct, China's National Knowledge Infrastructure, and the Wanfang database. We retrieved studies published before December 2022 that met the inclusion criteria, including clinical controlled trials (randomized controlled trials) and clinical noncontrolled trials (non-randomized controlled trials) on the use of Ahmed glaucoma valve in pediatric patients with refractory glaucoma.
Postmarketing Safety Surveillance of Topiramate: A Signal Detection and Analysis Study Based on the FDA Adverse Event Reporting System Database.
J Evid Based Med
December 2024
School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, China.
Article Synopsis
- This study investigates adverse events associated with topiramate using data from the FDA Adverse Event Reporting System, aiming to improve its safe clinical use.
- The analysis reviewed 12,168 reports and identified 244 positive signals of adverse reactions, with 21 of these being serious and not listed on the drug label.
- Key serious signals included conditions like hypospadias, spina bifida, and renal dysfunction, highlighting the necessity for ongoing vigilance in monitoring topiramate's safety.
In-Office Suprachoroidal Viscopexy for Acute Rhegmatogenous Retinal Detachment.
JAMA Ophthalmol
January 2025
Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada.
Importance: In-office suprachoroidal viscopexy (SCVEXY) is a relatively new procedure for rhegmatogenous retinal detachment (RRD), but minimal information is available regarding outcomes and safety.
Objective: To report outcomes with in-office SCVEXY for primary acute RRD.
Design, Setting, And Participants: This retrospective case series was conducted at St Michael's Hospital in Toronto, Ontario, Canada from June 2023 to February 2024 among consecutive patients with primary acute RRDs who presented with retinal tears that were reachable with the current in-office SCVEXY technique in the temporal or nasal retina.
Choroidal effusion after initiation of topical dorzolamide treatment.
BMJ Case Rep
November 2024
Ophthalmology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
We report a case of unilateral serous choroidal effusion in a patient without prior glaucoma surgeries that developed within 1 week of starting topical dorzolamide. A Caucasian female in her 60s with a history of severe primary open-angle glaucoma in the left eye without prior glaucoma surgeries developed irritation and subsequently blurry vision in her left eye within 1 week of starting topical dorzolamide 2% in the left eye only. Funduscopic exam and B-scan ultrasound demonstrated a serous choroidal effusion in the nasal and temporal periphery.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!